腔内灌注化疗联合全身热疗治疗恶性胸腹腔积液临床研究

目的探讨腔内化疗联合全身热疗对恶性腔内积液的疗效及毒副作用。方法回顾分析64例胸腹水患者。分为A、B两组,A组34例为单纯腔内化疗组,行腔内中心静脉置管抽液后注入化疗药物,B组30例为热化疗组,行腔内置管抽液化疗联合全身热疗。两组均为每周1次共4次,评价两组患者的近期疗效及毒副作用。结果A组患者CR为29.41%(10/34),PR为32.35%(11/34),有效率(CR PR)为61.76%,B组患者CR为46.67%(14/30),PR为40%(12/30),有效率(CR PR)为86.67%,两组间比较差异有显著性(P=0.045)。毒副作用方面,消化道反应(I° II°)与血液学毒性(I° II°)两组间均无明显差异(P=1.000)。结论腔内灌注化疗联合全身热疗治疗恶性胸腹腔积液较单纯腔内化疗疗效高,耐受性良好。

Intracavitary perfusing chemotherapy combined with WBH for patients with malignant hydrothorax and seroperitoneum

[Objective] To study the shot-term effects and toxicities of intracavitary chemotherapy combined with the WBH (whole body thermotherapy) for patients with malignant hydrothorax and seroperitoneum. [Methods] 64 patients with malignant hydrothorax and seroperitoneum were studied respectively. 34 patients in group A only received intracavitary chemotherapy, while the other 30 patients in group B received intracavitary chemotherapy combined with WBH. Every patient received the treatment once a week and four times in total. [Results] The overall response rate was 61.76%, including CR 29.41% and PR 32.35% in group A; while in group B, the overall response rate was 86.67%, including CR 46.67% and PR 40.00%. Group comparison between A and B showed significant difference (P =0.045). Toxicities of digestive reaction and myelosuppression showed no significant difference(P=1.000). [Conclusions] Intracavitary chemotherapy combined with the WBH for patients with malignant hydrothorax and seroperitoneum is more efficient and better tolerated.